Alvotech (ALVO) Non-Current Deffered Revenue (2020 - 2025)
Alvotech (ALVO) reported Non-Current Deffered Revenue of $5.5 million for Q4 2025, down 93.19% on a YoY basis from $80.7 million in Q4 2024, and down 93.19% quarter-over-quarter from $80.7 million in Q4 2024.
Alvotech (ALVO) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Alvotech has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $5.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 93.19% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.5 million (down 93.19% YoY), and the FY2025 full-year result was $5.5 million, down 93.19% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $5.5 million, down from $80.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $80.7 million in Q4 2024, with the low at $5.5 million in Q4 2025.
- Historically, Non-Current Deffered Revenue has averaged $52.3 million across 5 years, with a median of $57.0 million in 2022.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 412.5% — and 2025, when it plunged 93.19%.
- Alvotech's Non-Current Deffered Revenue stood at $44.8 million in 2021, then grew by 27.15% to $57.0 million in 2022, then gained by 28.49% to $73.3 million in 2023, then rose by 10.18% to $80.7 million in 2024, then sank by 93.19% to $5.5 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $5.5 million (Q4 2025), $80.7 million (Q4 2024), and $73.3 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Alvotech | 12.16 Mn | -160.20 Mn | -22.39 Mn | 5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.50 Mn |
| Dec 31, 2024 | 80.72 Mn |
| Dec 31, 2023 | 73.26 Mn |
| Dec 31, 2022 | 57.02 Mn |
| Dec 31, 2021 | 44.84 Mn |
| Dec 31, 2020 | 8.75 Mn |